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Essentials
• Deep vein thrombosis (DVT) has a large unknown
genetic component.
• We sequenced coding areas of 734 hemostasis-related
genes in 899 DVT patients and 599 controls.
• Variants in F5, FGA-FGG, CYP4V2-KLKB1-F11, and
ABO were associated with DVT risk.
• Associations in KLKB1 and F5 suggest a more complex
genetic architecture than previously thought.
Summary. Background: Although several genetic risk fac-
tors for deep vein thrombosis (DVT) are known, almost
all related to hemostasis, a large genetic component
remains unexplained. Objectives: To identify novel genetic
determinants by using targeted DNA sequenc-
ing. Patients/Methods: We included 899 DVT patients
and 599 controls from three case–control studies (DVT-
Milan, Multiple Environmental and Genetic Assessment
of risk factors for venous thrombosis [MEGA], and the
Thrombophilia, Hypercoagulability and Environmental
Risks in Venous Thromboembolism [THE-VTE] study)
for sequencing of the coding regions of 734 genes
involved in hemostasis or related pathways. We
performed single-variant association tests for common
variants (minor allele frequency [MAF] ≥ 1%) and gene-
based tests for rare variants (MAF ≤ 1%), accounting for
multiple testing by use of the false discovery rate
(FDR). Results: Sixty-two of 3617 common variants were
associated with DVT risk (FDR < 0.10). Most of these
mapped to F5, ABO, FGA–FGG, and CYP4V2–KLKB1–
F11. The lead variant at F5 was rs6672595 (odds ratio
[OR] 1.58, 95% confidence interval [CI] 1.29–1.92), in
moderate linkage with the known variant rs4524. Recipro-
cal conditional analyses suggested that intronic variation
might drive this association. We also observed a secondary
association at the F11 region: missense KLKB1 variant
rs3733402 remained associated conditional on known vari-
ants rs2039614 and rs2289252 (OR 1.36, 95% CI 1.10–
1.69). Two novel variant associations were observed, in
CBS and MASP1, but these were not replicated in the
meta-analysis data from the International Network against
Thrombosis (INVENT) consortium. There was no support
for a burden of rare variants contributing to DVT risk
(FDR > 0.2). Conclusions: We confirmed associations
between DVT and common variants in F5, ABO, FGA–
FGG, and CYP4V2–KLKB1–F11, and observed secondary
signals in F5 and CYP4V2–KLKB1–F11 that warrant repli-
cation and fine-mapping in larger studies.
Keywords: deep vein thrombosis; DNA sequencing;
genetics; risk factors; single-nucleotide polymorphisms.
Introduction
The hemostatic system ensures the delicate balance
between clotting and bleeding. Disturbance of this bal-
ance towards clotting may lead to venous thrombosis
(VT), mainly manifested as pulmonary embolism (PE) or
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deep vein thrombosis (DVT) [1,2]. Abnormal levels of
both fibrinolytic and coagulation factors have been asso-
ciated with VT risk [3–6]. The role of platelets as a risk
factor is less well studied, with conflicting results being
reported for associations between VT and several platelet
markers [7,8]. In addition, genetic variants, predominantly
in genes encoding proteins of the hemostatic system, have
been linked to VT risk [9]. Deficiencies of the natural
anticoagulants antithrombin, protein C and protein S
were among the first identified genetic causes of VT, and
hundreds of (mainly rare) mutations have since been
reported [10]. Two recent meta-analyses of genome-wide
association studies (GWASs), each including > 6000
patients and a multifold of controls, confirmed the associ-
ation of six loci and identified three novel loci [11,12]. The
established loci all map to genes related to hemostasis,
specifically: F5, FGG, F11, ABO, F2, and PROCR [9–12].
Two of the novel loci (TSPAN15 and SLC44A2), and
potentially a third locus at HIVEP1 identified in an earlier
GWAS [13] but not confirmed in the latest meta-analyses
[11,12], are the only replicated loci not directly connected
to the hemostatic system. This suggests that genes regulat-
ing (components of) the hemostatic system are the main
genetic contributors to VT risk.
Although VT has a strong genetic basis, with heritabil-
ity estimates of 50–60% [14–16], the established genetic
risk factors explain only a small proportion of the pheno-
typic variance [17]. In addition, the genetic component
remains unknown in 30% of families with multiple family
members affected by VT [18]. GWAS efforts have had
limited success in identifying novel genetic risk factors,
which were mainly common variants in hemostatis-related
genes with small effects on VT risk. Therefore, a focus on
rare and low-frequency variants in coding regions of the
genome may help to discover novel determinants of VT.
In this respect, we have previously shown that a burden
of rare coding ADAMTS13 variants is associated with a
4.8-fold increased DVT risk [19].
To extend the GWAS efforts, we performed targeted
DNA sequencing of the coding regions of 734 genes that
were or could be related to the hemostatic system in 899
DVT patients and 599 controls. We subsequently sought
replication for associated variants by using meta-analysis
data from the International Network against Thrombosis
(INVENT) consortium [11].
Patients and methods
Study population
We set up the Milan Leiden Sequencing study (MILES), in
which we included patients with a first VT and controls
without a history of VT from three population-based case–
control studies: DVT-Milan, Multiple Environmental and
Genetic Assessment of risk factors for venous thrombosis
(MEGA), and the Thrombophilia, Hypercoagulability and
Environmental Risks in Venous Thromboembolism (THE-
VTE) study. All studies have been previously described in
detail [19–21]. Briefly, DVT-Milan recruited 2139 consecu-
tive patients with a first DVT at the Angelo Bianchi Bonomi
Hemophilia and Thrombosis Center in Milan (Italy)
between 1995 and 2010 [19]. Controls were non-consangui-
neous relatives, partners, or friends who accompanied
patients to center visits. In MEGA, 4956 consecutive
patients with a first DVT or PE were recruited at six antico-
agulation clinics in the Netherlands between 1999 and 2004
[20]. Partners of patients were invited to participate as con-
trol subjects. Additional controls were recruited from the
general population by the use of random digit dialing.
Patients and controls were invited to provide a blood sample
up to 2002, after which we switched, for logistical reasons,
to buccal swabs. The THE-VTE study is a two-center case–
control study with a similar design as MEGA, in which 796
consecutive patients with a first DVT or PE and 531 controls
were enrolled in Leiden (the Netherlands) and Cambridge
(UK) between 2003 and 2008 [21]. Again, partners of eligible
patients were invited to participate as controls.
From each study, we included patients and controls on
the basis of the following criteria: high-quality DNA sam-
ple available from blood, European ancestry as defined
by self-reported country of birth of the parents, no major
surgery or cancer diagnosis related to the index date, and
no deficiency of the natural anticoagulant proteins,
defined as having normal levels of protein C, protein S,
and antithrombin. To eliminate two major genetic causes
of VT, we included patients and controls who did not
carry factor V (FV) Leiden (rs6025) or prothrombin (PT)
G20210A (rs1799963). In addition, we oversampled
patients who had a recurrence during the follow-up stud-
ies of MEGA and the THE-VTE study (N = 241), as
these are more likely to carry genetic risk factors for VT.
To ensure a sufficient sample size, we allowed recurrent
VT patients to carry FV Leiden or PT G20210A
(N = 94). In total, 899 DVT patients and 599 controls
were selected for sequencing. An overview of the partici-
pants per study is shown in Table S1.
All participants provided written informed consent.
DVT-Milan was approved by the Institutional Review
Board of the Fondazione IRCCS Ca’ Granda–Ospedale
Maggiore Policlinico, whereas MEGA and the THE-VTE
study were approved by the Medical Ethics Committee of
the Leiden University Medical Center. The THE-VTE
study was also approved by the National Health Service
Research Ethics Committee in Cambridge.
Targeted DNA sequencing
We selected pathways involved in thrombosis and
hemostasis, including the coagulation system, fibrinolysis,
platelet function, inflammation, and the complement sys-
tem. Using literature and gene ontology databases, we
extracted genes belonging to these pathways. From the
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ThromboGenomics database [22], we included additional
genes that have been linked to inherited clotting, platelets,
or bleeding disorders. In total, we included 734 genes,
and sequenced the coding regions plus 10 bp flanking the
exons to cover the splice junctions. For a subset of 48
genes, we additionally sequenced the 30-untranslated
region (UTR) and the 50-UTR. In addition, we performed
whole gene sequencing including the 10-kbp promoter
areas of three genes, i.e. F5, VWF, and F8, which are of
particular interest for VT. F5 harbors the strongest
genetic risk factor for VT, i.e. FV Leiden, in the general
population. Von Willebrand factor and FVIII, encoded
by VWF and F8, are tightly interconnected proteins
whose levels are strongly associated with first and recur-
rent VT risk [5,23]. We also targeted 179 single-nucleotide
variants, consisting of 28 variants previously associated
with VT and 151 ancestry-informative markers. To facili-
tate the capture, we allowed some 200 bp of target region
surrounding each variant. A list of the targeted genes and
variants is shown in Table S2.
The target area was designed with the Reference
Sequence (RefSeq) Database by the use of tools in the
University of California Santa Cruz Genome Browser
[24], and sent to NimbleGen (Roche NimbleGen, Madi-
son, WI, USA) for probe design. Next-generation DNA
sequencing was subsequently performed at the Human
Genome Sequencing Center (HGSC), Baylor College of
Medicine (Houston, TX, USA). A complete sequencing
protocol can be accessed on the HGSC website (https://
www.hgsc.bcm.edu/content/protocols-sequencing-library-
construction). Briefly, Illumina paired-end pre-capture
libraries were constructed from extract DNA according to
the manufacturer’s protocol (Illumina Multiplexing_Sam-
plePrep_Guide_1005361_D) with some minor modifica-
tions. We multiplexed 24 samples per capture, and
included two capture pools per HiSeq lane. Enriched
samples were sequenced with the HiSeq 2000 platform
(Illumina, San Diego, CA, USA).
Sequence analysis was performed with the MERCURY
analysis pipeline [25]. In short, sequence reads and base-
call confidence values were generated for demultiplexed
pools with the vendor’s primary analysis software
(CASAVA). Next, reads and qualities were mapped to refer-
ence genome hg19 by use of the Burrows–Wheeler aligner
[26], resulting in BAM files per sample [27]. Realignment
around insertions and deletions (indels), and recalibration
of quality scores, were performed with the GENOME ANALY-
SIS TOOLKIT [28]. Variant calling was conducted with the
ATLAS2 suite [29], and this was followed by variant anno-
tation as implemented in the CASSANDRA annotation suite.
Individual variant files were subsequently merged into a
project-level file to generate a genotype matrix of all iden-
tified variants.
Initial exclusion criteria for variant calls were as fol-
lows: variant posterior probability of < 0.95, < 3 variant
reads, variant read ratio of < 0.1, variant reads in a single
strand direction, and total coverage of < 6 or > 1024
reads. Called variants that passed quality control in at
least one individual were included in the project-level
variant file. In total, 31 540 variants were identified in
1495 individuals with sequencing data available (897
DVT patients and 598 controls). We subsequently per-
formed additional filtering with VCFTOOLS [30] to identify
high-quality variants, requiring a sequencing depth of
≥ 10 reads, a call rate of ≥ 80%, a Phred score of ≥ 30,
and Hardy–Weinberg equilibrium P > 1.0 9 104 in the
controls separately per study. A total of 20 054 variants
passed quality control.
Statistical analysis
We conducted single-variant association analyses for 3617
low-frequency and common variants, defined as a minor
allele frequency (MAF) of ≥ 1%, by using logistic regres-
sion as implemented in PLINK [31]. We calculated effect
estimates as odds ratios (ORs) with corresponding 95%
confidence intervals (CIs) per risk allele copy, and adjusted
for sex, age, (study) origin, carriership of FV Leiden per
allele copy, and carriership of PT G20210A. We assumed
that X-chromosomal loci undergo complete inactivation.
Linkage disequilibrium (LD) between variants was
assessed in Europeans from the 1000 Genomes Project
[32]. To identify secondary associations, we performed
conditional analyses by adjusting for the lead variant at a
locus (defined as region within 1 Mb of the lead variant).
The Bonferroni threshold for significance was set at
1.38 9 105 (0.05 divided by 3617 variants) to account for
multiple testing. We additionally calculated false discovery
rates (FDRs), and variants with a FDR of < 0.10 were
carried forward for replication.
Rare variants (MAF ≤ 1%) were collapsed per gene
and analyzed with the T1 burden test and the Sequence
Kernel Association Test (SKAT) [33], the latter allowing
differential effect directions. In total, we analyzed 16 188
variants in 647 genes with a cumulative minor allele count
(cMAC) of ≥ 5. Analyses were adjusted for sex, age,
(study) origin, and carriership of FV Leiden and
PT G20210A. In the burden test, we used adaptive per-
mutations to calculate empirical P-values, which were
stratified by northwestern versus southern European ori-
gin. We calculated FDRs to take multiple testing into
account. To identify which rare variant contributed to an
association signal, we excluded one variant at a time and
repeated the analyses. The gene-based association tests
were performed with the PLINK/SEQ suite.
Replication
Novel associations between common and low-frequency
variants and DVT (FDR < 0.10) were examined in meta-
analysis data from the INVENT consortium. Details of
the meta-analysis and the included studies are provided
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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elsewhere [11]. In short, GWAS data from 12 studies,
including 7507 VT patients and 52 632 controls, were
meta-analyzed with an inverse-variance weighting fixed-
effects model. It is of note that there was a small amount
of overlap in VT patients (N = 384) between the discov-
ery and the replication analyses, as some patients were
also included in the meta-analysis of the INVENT con-
sortium.
Results
Targeted DNA sequencing was successfully performed in
897 DVT patients and 598 controls. The study population
characteristics are shown in Table 1. In total, 20 054
high-quality variants were identified, of which 11 268
were singletons (median of seven singletons per person;
interquartile range of 4–10). An overview of the func-
tional classes and the MAF distribution is shown in
Fig. S1. The majority of the variants were rare and
mapped to protein-coding sequences (N = 10 131), includ-
ing several stop-loss and stop-gain variants. We also
observed 168 indels and 530 splice variants. In addition,
we identified a total of 5210 variants that had not been
reported in any database.
Single-variant association analyses
We tested 3617 low-frequency and common variants for
an association with DVT risk. The quantile–quantile plot
of the observed P-values versus the expected distribution
is shown in Fig. S2. Statistically significant associations at
the Bonferroni threshold were observed for 12 variants in
four loci: ABO, FGA–FGG, CYP4V2–KLKB1–F11, and
F5 (Table 2). All four loci harbor established genetic risk
factors for VT. Interestingly, only three of the 12 variants
mapped to coding sequences. The exclusion of recurrent
VT patients in a sensitivity analysis resulted in similar
associations with DVT risk (Table S3). The lead variant
in ABO was the well-known risk variant rs8176719 (fra-
meshift variant; risk allele frequency [RAF] of 45%),
encoding non-O blood groups. C-carriers had a 1.9-fold
(95% CI 1.61–2.24) increased DVT risk per allele copy.
The intronic ABO variant rs4962040 also reached statisti-
cal significance (RAF 59%, OR 1.53, 95% CI 1.28–1.83),
although this association was diminished upon condition-
ing on rs8176719 (ORadjusted 1.12, 95% CI 0.88–1.41).
Likewise, none of the other 22 ABO variants was associ-
ated with DVT risk conditional on rs8176719 (Table S4).
In CYP4V2–KLKB1–F11, the lead variant was intronic
F11 variant rs2036914 (RAF 60%, OR 1.65,
95% CI 1.38–1.97), which has been linked to increased
FXI levels and VT [34,35]. Three additional variants were
associated with DVT risk at the Bonferroni threshold,
one of which remained associated upon conditioning on
Table 1 Study population characteristics
DVT patients Controls
N 897 598
Age (years), mean (SD) 48.1 (13.7) 47.1 (13.3)
Male sex, n (%) 449 (50.1) 277 (46.3)
Northwestern European origin, n (%) 599 (67.8) 300 (50.2)
DVT only, n (%) 755 (84.2) NA
PT G20210A carriers*, n (%) 15 (1.67) NA
FVL carriers*, n (%) 75 (8.36) NA
DVT, deep vein thrombosis; FVL, factor V Leiden; NA, not applica-
ble; PT, prothrombin; SD, standard deviation. *These formed part
of a subgroup of 241 DVT patients who had a recurrence during fol-
low-up in MEGA and THE-VTE study (prevalences of FVL and PT
G20210A in that subgroup of 31.1% and 6.2%, respectively).
Table 2 Associations between common variants and first deep vein thrombosis (P < 1.38 9 105)
rsID Chromosome Position Class Gene A1/A2 RAF
Discovery analysis Conditional analysis*
OR (95% CI) P-value OR (95% CI)* P-value
rs3766110 1 169515183 Intronic F5 C/A 0.774 1.54 (1.27–1.86) 1.07 9 105 NA NA
rs3766111 1 169515204 Intronic F5 C/T 0.773 1.57 (1.29–1.91) 6.82 9 106 NA NA
rs3766113 1 169515307 Intronic F5 G/A 0.770 1.55 (1.28–1.88) 8.59 9 106 NA NA
rs6672595 1 169515536 Intronic F5 T/C 0.757 1.58 (1.29–1.92) 6.11 9 106 NA NA
rs6050 4 155507590 Missense FGA T/C 0.393 1.66 (1.37–2.02) 2.33 9 107 NA NA
rs2066865 4 155525276 Downstream FGG G/A 0.352 1.60 (1.33–1.92) 4.86 9 107 1.36 (0.81–2.31) 0.245
rs3733402 4 187158034 Missense KLKB1 G/A 0.573 1.55 (1.30–1.86) 1.27 9 106 1.33 (1.08–1.64) 0.006
rs4253399 4 187188094 Intronic F11 T/G 0.458 1.50 (1.27–1.76) 8.34 9 107 1.16 (0.90–1.49) 0.246
rs3822057 4 187188152 Intronic F11 A/C 0.545 1.44 (1.23–1.70) 6.74 9 106 0.91 (0.62–1.35) 0.642
rs2036914 4 187192481 Intronic F11 T/C 0.602 1.65 (1.38–1.97) 2.47 9 108 NA NA
rs8176719 9 136132908 Frameshift ABO T/TC 0.451 1.90 (1.61–2.24) 1.39 9 1014 NA NA
rs4962040 9 136133531 Intronic ABO G/A 0.594 1.53 (1.28–1.83) 3.67 9 106 1.12 (0.88–1.41) 0.355
A1, reference allele; A2, risk allele; CI, confidence interval; NA, not applicable; OR, odds ratio; RAF, risk allele frequency. Single-variant asso-
ciation analyses for 3617 low-frequency and common variants (minor allele frequency of > 1%) were conducted with logistic regression on the
assumption of an additive mode of inheritance. Analyses were adjusted for sex, age, (study) origin, carriership of factor V Leiden per copy of
the risk allele, and carriership of prothrombin G20210A. *We conducted conditional logistic regression analyses in which we adjusted for the
lead variant per locus (highlighted in bold, i.e. F5 rs6672595, FGA rs6050, F11 rs2036914, and ABO rs8176719).
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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rs2036914 (rs3733402 in KLKB1, ORadjusted 1.33,
95% CI 1.08–1.64). Conditioning on a second known F11
risk variant (rs2289252) did not materially change this
association (ORadjusted 1.36, 95% CI 1.10–1.69). The
KLKB1 missense variant (p.Ser143Asn) leads to reduced
binding of prekallikrein to its cofactor high molecular
weight kininogen [36], affecting the initiation of the
intrinsic coagulation cascade. In the FGA–FGG locus, the
association with DVT was driven by missense FGA vari-
ant rs6050 (RAF 39%, OR 1.66, 95% CI 1.37–2.02) and
downstream FGG variant rs2066865 (RAF 35%,
OR 1.60, 95% CI 1.33–1.92), which have both been
linked to increased c0-fibrinogen levels and VT risk
[37,38]. rs6050 and rs2066865 were in high LD
(r2 = 0.90), and reciprocal conditional analysis showed
that they represented the same association signal
(Table S5). We did not identify additional associations
after conditioning on the lead variants (Table S4). Four
intronic F5 variants were associated with DVT risk at the
Bonferroni threshold, were in almost complete LD (the
lowest r2 between any pair was 0.90), and represented the
same association signal. Carriers of the lead variant
(rs6672595, RAF 76%) had a 1.6-fold increased DVT risk
(95% CI 1.29–1.92) per risk allele. The variants were also
in high LD (r2 = 0.77) with F5 missense variant rs4524, for
which an association with VT independently of FV Leiden
has been reported [39]. In our study, carriers of rs4524
(RAF 73%) had a 1.3-fold higher DVT risk
(95% CI 1.11–1.60) per allele copy, which was attenuated
with adjustment for lead variant rs6672595 (ORadjusted 1.10,
95% CI 0.74–1.63). On the other hand, the association
between rs6672595 (and its proxies) and DVT risk
remained, albeit with wider CIs, with adjustment for rs4524
(Table S6). No secondary association signals were observed
in the F5 region (Fig. S3).
In addition, we observed 50 variants that did not
exceed the Bonferroni threshold for statistical significance,
but did have low FDRs (< 0.10). Almost all of these
mapped to the four main loci and did not represent new
association signals (Table S7). We additionally identified
two novel, suggestive variant associations with DVT risk
(Table 3). In MASP1, we observed an association with
DVT for 30-UTR variant rs72549167 (RAF 1.6%,
FDR 9%). Carriers of the risk allele had a 3.5-fold
increased DVT risk (95% CI 1.62–7.67) per allele copy.
MASP1 encodes mannan-binding lecture serine pepti-
dase 1, which is involved in the lectin pathway of comple-
ment activation and has crosslinks with the clotting
cascade [40,41]. In particular, when activated by thrombin
and activated platelets [42], MASP1 can cleave several
coagulation factors, including PT, thrombin-activatable
fibrinolysis inhibitor, and FXIII [41]. Of the other 16
MASP1 variants, one was also associated with DVT risk
(Table S8), and was in complete LD with rs72549167.
The other novel variant mapped to a synonymous variant
in CBS, encoding cystathionine b-synthase, and was T
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associated with DVT risk with an allelic OR of 1.31
(95% CI 1.11–1.55, FDR 9%). Cystathionine b-synthase
catalyzes the conversion of homocysteine to cystathionine,
and specific genetic defects in CBS lead to homocystin-
uria, a disorder that has been linked to increased VT risk
[43]. We observed two additional common variants in
CBS, not associated with rs1801181, and neither of these
was associated with DVT risk (Table S9). We next aimed
to replicate the two novel variant associations by using
the meta-analysis data from the INVENT consortium,
which included 7507 VT patients and 52 632 controls
(Table 3). There was no clear evidence for an association
of DVT with rs72549167 in MASP1 (OR 1.21,
95% CI 0.96–1.52) or with rs1801181 in CBS (OR 1.00,
95% CI 0.96–1.05).
Gene-based association analyses
The impact of 16 188 rare variants mapping to 647 genes
(cMAC ≥ 5) on DVT risk was assessed with aggregation
tests. The results from the SKAT-based joint analyses of
all rare variants per gene did not provide support for an
association between rare variants and DVT risk. The
most suggestive association signal was observed for
F2RL2 (P = 0.0013, FDR 60%), encoding proteinase-
activated receptor (PAR)-3. The burden tests identified
one gene suggestive of an association with DVT risk.
DVT patients had a burden of rare variants in KLK5
(P = 0.0003, FDR 21%), which encodes a serine protease
named kallikrein-related peptidase 5 and is involved in
inflammatory responses through the PAR-2 system [44].
Of the 10 rare variants identified in KLK5, including five
singletons, 26 variant alleles were observed in DVT
patients as compared with three alleles in controls. All 10
variants mapped to protein-coding sequences. None of
the variants was solely driving the association signal (data
not shown).
Discussion
To identify novel genetic risk factors for DVT that have
been missed by GWAS, we sequenced the coding regions
of 734 genes related to hemostasis in 899 DVT patients
and 599 controls. Our targeted sequencing approach con-
firmed several established risk loci. Specifically, lead vari-
ants at ABO, FGA–FGG and CYP4V2–KLKB1–F11 have
all previously been implicated in VT risk, both directly
and via proxy variants [11–13,19,34–36]. The effect sizes
observed in our study were slightly higher than those in
earlier reports, which may, in part, be explained by our
selection of individuals without a cancer diagnosis or
recent surgery. Differences in genetic effects on PE versus
DVT could also have played a role, in line with the so-
called ‘FV Leiden paradox’ [45]. Although we did not dis-
cover novel risk loci, the secondary risk loci identified at
F5 and CYP4V2–KLKB1–F11 may provide leads for a
better understanding of the biological mechanism under-
lying these loci.
Interestingly, almost all associated variants mapped to
non-coding sequences, whereas our sequencing design
mainly targeted coding variation. In F5 and CYP4V2–
KLKB1–F11, there was little evidence that the (lead)
associations could be explained by linkage to common,
coding variants. This may point to non-coding variation
as a causal risk factor, potentially influencing DVT risk
by affecting gene regulation. Four co-inherited intronic
variants in F5, which have not been implicated in VT
risk, were associated with DVT risk at the Bonferroni
threshold. Missense F5 variant rs4524, which is an estab-
lished risk variant independent of FV Leiden [38] and is
in moderate LD with the associated F5 variants, did not
attain a high level of statistical significance in our study.
Furthermore, its effect on DVT risk was strongly dimin-
ished after adjustment for our lead F5 variant
(rs6672595). Both variants are part of a large, strongly
linked cluster of variants that spans across several
introns and exons of F5. Additional fine-mapping in a
large study is necessary to uncover the most likely causal
variant. Another notable finding was the suggestive, sec-
ondary association signal at CYP4V2–KLKB1–F11, i.e.
missense KLKB1 variant rs3733402, which remained
associated with DVT risk with an allelic OR of 1.4 after
adjustment for rs2036914 and rs2289252. We are not the
first to report an association signal at CYP4V2–KLKB1–
F11 secondary to rs2289252 and rs2036914 [11,34],
although the previously reported variants are not in LD
with rs3733402, suggesting that this locus may indeed
harbor multiple causal variants. In addition, we were
unable to disentangle the effects of FGA rs6050 and
FGG rs2068865 on DVT risk, owing to their strong,
although imperfect, linkage. However, a previously
reported haplotype analysis did not show an independent
association with VT for the haplotype carrying FGA
rs6050 [36].
In addition to the associations at the known loci, we
identified two variants that have not been linked to VT
risk, with low FDRs but association tests that did not
pass the Bonferroni threshold. These were a synonymous
variant in CBS and a 30-UTR variant in MASP1. Nei-
ther variant, however, was replicated in the meta-analy-
sis data from the INVENT consortium. Imputation
quality was sufficient and there was no evidence of sta-
tistical heterogeneity. We cannot rule out the possibility
that differences in the discovery and the replication
study populations, e.g. owing to the inclusion of DVT
patients versus patients with any VT event, could have
explained the lack of replication. Alternatively, the asso-
ciations in the discovery analysis might have been
chance findings, taking into account the FDR of 9% for
both variants.
The gene-based analyses did not support the hypothe-
sis of a burden of rare, mainly coding variants in
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hemostasis-related genes contributing to DVT risk. We
observed a potential association for a burden of rare
variants in KLK5, with 26 alleles being observed in DVT
patients as compared with three alleles in controls,
although the FDR was relatively high (21%). The lack
of significant gene associations may be explained by our
limited sample size. Gene-based analyses for complex dis-
eases generally require large study sizes, given the proba-
bly modest effect sizes and the expected proportion of
causal variants [46]. Therefore, we might have missed
associations between genes with rare variants and DVT
risk. We also did not distinguish between rare variants
with or without a predicted deleterious consequence, as
advocated by some [46,47], because this would have fur-
ther increased the multiple testing burden and lowered
cMACs. As the effects of VT on fitness are limited, we
also did not expect strong purifying selection on deleteri-
ous variants. In addition, our group has previously
reported an association between DVT and a burden of
rare coding variants in ADAMTS13 (17 alleles in DVT
patients as compared with four alleles in controls,
N = 192 individuals) [19]. In the present study, we
observed a nominal association for a burden of rare vari-
ants in ADAMTS13 with DVT risk (P = 0.048, 84 alleles
in DVT patients as compared with 42 alleles in controls).
Although the majority of studied rare ADAMTS13 vari-
ants mapped to coding sequences (75%), the inclusion of
non-coding variants may explain the difference in the
results of the burden analyses. However, when we
focused only on rare coding variants in ADAMTS13, we
observed a similar association with DVT risk (P = 0.066,
55 alleles in DVT patients as compared with 27 alleles in
controls). Larger studies are needed to elucidate the role
of rare coding and non-coding variants in ADAMTS13
in DVT risk.
The major limitation of our study is its limited sample
size, which prevented us from detecting associations
across the entire allele frequency spectrum. Given the
multicausal nature of DVT, estimates of genetic effects on
DVT risk are expected to be modest, requiring an even
larger sample size. We attempted to maximize our statisti-
cal power by studying genetic variation in biologically
plausible genes in a well-characterized study population.
Specifically, we selected genetically enriched DVT
patients, without some of the major clinical risk factors.
In addition, we oversampled VT patients who had devel-
oped a recurrence and are therefore more likely to carry
genetic risk variants. Except for a small number of
patients with recurrent VT, we selected individuals not
carrying FV Leiden and PT G20210A, and could there-
fore not study these variants or those in strong LD.
Another limitation is the lack of generalizability of our
findings to non-European populations. In addition, by
design, our targeted sequencing approach did not allow
us to study variation in regulatory regions outside our
target area or variation in genes not previously linked to
the hemostatic system. Therefore, we were unable to iden-
tify variants in untargeted regions of the candidate genes
or novel DVT-associating genes outside the hemostatic
system, or to assess variation in the recently identified
risk loci SLC44A2 and TSPAN15 [11].
In conclusion, our targeted sequencing approach con-
firmed the association of several of the established VT
risk loci. The secondary loci identified at F5 and
CYP4V2–KLKB1–F11 suggest that the underlying biolog-
ical mechanism might be more complex than initially
thought. In addition, we did not find evidence of a bur-
den of rare variants in hemostasis-related genes affecting
DVT risk.
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